Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

Phase 2 Completed 73 enrolled Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 2b open label study of an orally administered LSD1 inhibitor, Bomedemstat (MK-3543, formerly called IMG-7289), in patients with essential thrombocythemia. This study investigates the following: * The safety and tolerability of Bomedemstat * The pharmacodynamic effect of Bomedemstat

Timeline

Start: 2020-09-08
Primary completion: 2023-03-23
Completion: 2023-03-23

Outcome

Met primary endpoint

registry NUMBER Bomedemstat: 76.6 (64.3 to 86.2) Percentage of Participants NCT04254978 ↗

registry analysis (superiority test); Bomedemstat; p <.0001; Exact binomial distribution NCT04254978 ↗

Publications

Results Gill H, Palandri F, Ross DM, Gothert JR, Cochrane T, Larsen SR, Halpern AB, Shortt J, Rossetti JM, Liang J, Marchetti M, Wilson AJ, Innes AJ, Hanna M, Vianelli N, Stevenson WS, Vannucchi AM, Kleppe M, Flynn J, Natsoulis G, Harrison CN, Rienhoff HY Jr. Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia. Blood Adv. 2026 May 26;10(10):3494-3504. doi: 10.1182/bloodadvances.2025017575.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bomedemstat	Small molecule	—	Oral